FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766504298> ?p ?o ?g. }

• W2766504298 endingPage "374" @default.
• W2766504298 startingPage "367" @default.
• W2766504298 abstract "Abstract Background Although opioid-induced nausea and vomiting (OINV) often result in analgesic undertreatment in patients with cancer, no randomized controlled trials have evaluated the efficacy of prophylactic antiemetics for preventing OINV. We conducted this randomized, placebo-controlled, double-blind trial to evaluate the efficacy and safety of prophylactic treatment with prochlorperazine for preventing OINV. Materials and Methods Cancer patients who started to receive oral oxycodone were randomly assigned in a 1:1 ratio to receive either prochlorperazine 5 mg or placebo prophylactically, given three times daily for 5 days. The primary endpoint was the proportion of patients who had a complete response (CR) during the 120 hours of oxycodone treatment. CR was defined as no emetic episode and no use of rescue medication for nausea and vomiting during 5 days. Key secondary endpoints were the proportion of patients with emetic episodes, proportion of patients with moderate or severe nausea, quality of life, and proportion of treatment withdrawal. Results From November 2013 through February 2016, a total of 120 patients were assigned to receive prochlorperazine (n = 60) or placebo (n = 60). There was no significant difference in CR rates (69.5% vs. 63.3%; p = .47) or any secondary endpoint between the groups. Patients who received prochlorperazine were more likely to experience severe somnolence (p = .048). Conclusion Routine use of prochlorperazine as a prophylactic antiemetic at the initiation of treatment with opioids is not recommended. Further research is needed to evaluate whether other antiemetics would be effective in preventing OINV in specific patient populations. Implications for Practice Prophylactic prochlorperazine seems to be ineffective in preventing opioid-induced nausea and vomiting (OINV) and may cause adverse events such as somnolence. Routine use of prophylactic prochlorperazine at the initiation of treatment with opioids is not recommended. Further research is needed to evaluate whether other antiemetics would be effective in preventing OINV in specific patient populations." @default.
• W2766504298 created "2017-11-10" @default.
• W2766504298 creator A5014174633 @default.
• W2766504298 creator A5032236530 @default.
• W2766504298 creator A5033279700 @default.
• W2766504298 creator A5041010343 @default.
• W2766504298 creator A5052637717 @default.
• W2766504298 creator A5054408940 @default.
• W2766504298 creator A5067680290 @default.
• W2766504298 creator A5067835462 @default.
• W2766504298 creator A5074278308 @default.
• W2766504298 creator A5074635182 @default.
• W2766504298 creator A5076545273 @default.
• W2766504298 creator A5078132380 @default.
• W2766504298 creator A5079533730 @default.
• W2766504298 date "2017-10-16" @default.
• W2766504298 modified "2023-10-02" @default.
• W2766504298 title "Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial" @default.
• W2766504298 cites W1567517895 @default.
• W2766504298 cites W1608689417 @default.
• W2766504298 cites W1760218964 @default.
• W2766504298 cites W1919200285 @default.
• W2766504298 cites W1966324171 @default.
• W2766504298 cites W1973714718 @default.
• W2766504298 cites W1998903692 @default.
• W2766504298 cites W2009070767 @default.
• W2766504298 cites W2011518853 @default.
• W2766504298 cites W2021247155 @default.
• W2766504298 cites W2055653516 @default.
• W2766504298 cites W2072575748 @default.
• W2766504298 cites W2076668534 @default.
• W2766504298 cites W2108802610 @default.
• W2766504298 cites W2112250288 @default.
• W2766504298 cites W2121723948 @default.
• W2766504298 cites W2123267000 @default.
• W2766504298 cites W2124742778 @default.
• W2766504298 cites W2132469876 @default.
• W2766504298 cites W2143841439 @default.
• W2766504298 cites W2149750503 @default.
• W2766504298 cites W2152166519 @default.
• W2766504298 cites W2157594275 @default.
• W2766504298 cites W2160670409 @default.
• W2766504298 cites W2162296777 @default.
• W2766504298 cites W2171072251 @default.
• W2766504298 cites W2191246714 @default.
• W2766504298 cites W2337210803 @default.
• W2766504298 cites W2507759964 @default.
• W2766504298 cites W4245726844 @default.
• W2766504298 cites W4322702919 @default.
• W2766504298 cites W4322702922 @default.
• W2766504298 doi "https://doi.org/10.1634/theoncologist.2017-0225" @default.
• W2766504298 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5905679" @default.
• W2766504298 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29038236" @default.
• W2766504298 hasPublicationYear "2017" @default.
• W2766504298 type Work @default.
• W2766504298 sameAs 2766504298 @default.
• W2766504298 citedByCount "11" @default.
• W2766504298 countsByYear W27665042982019 @default.
• W2766504298 countsByYear W27665042982020 @default.
• W2766504298 countsByYear W27665042982021 @default.
• W2766504298 countsByYear W27665042982022 @default.
• W2766504298 countsByYear W27665042982023 @default.
• W2766504298 crossrefType "journal-article" @default.
• W2766504298 hasAuthorship W2766504298A5014174633 @default.
• W2766504298 hasAuthorship W2766504298A5032236530 @default.
• W2766504298 hasAuthorship W2766504298A5033279700 @default.
• W2766504298 hasAuthorship W2766504298A5041010343 @default.
• W2766504298 hasAuthorship W2766504298A5052637717 @default.
• W2766504298 hasAuthorship W2766504298A5054408940 @default.
• W2766504298 hasAuthorship W2766504298A5067680290 @default.
• W2766504298 hasAuthorship W2766504298A5067835462 @default.
• W2766504298 hasAuthorship W2766504298A5074278308 @default.
• W2766504298 hasAuthorship W2766504298A5074635182 @default.
• W2766504298 hasAuthorship W2766504298A5076545273 @default.
• W2766504298 hasAuthorship W2766504298A5078132380 @default.
• W2766504298 hasAuthorship W2766504298A5079533730 @default.
• W2766504298 hasBestOaLocation W27665042981 @default.
• W2766504298 hasConcept C121608353 @default.
• W2766504298 hasConcept C126322002 @default.
• W2766504298 hasConcept C141071460 @default.
• W2766504298 hasConcept C142724271 @default.
• W2766504298 hasConcept C168563851 @default.
• W2766504298 hasConcept C170493617 @default.
• W2766504298 hasConcept C203092338 @default.
• W2766504298 hasConcept C204787440 @default.
• W2766504298 hasConcept C27081682 @default.
• W2766504298 hasConcept C2776029756 @default.
• W2766504298 hasConcept C2778904085 @default.
• W2766504298 hasConcept C2780580376 @default.
• W2766504298 hasConcept C2780852908 @default.
• W2766504298 hasConcept C2780884295 @default.
• W2766504298 hasConcept C2781063702 @default.
• W2766504298 hasConcept C2781324269 @default.
• W2766504298 hasConcept C42219234 @default.
• W2766504298 hasConcept C71924100 @default.
• W2766504298 hasConceptScore W2766504298C121608353 @default.
• W2766504298 hasConceptScore W2766504298C126322002 @default.
• W2766504298 hasConceptScore W2766504298C141071460 @default.

• next